# A drug trial that worked too well to continue - Date: 2026-04-06 - Category: Biotech & Life Sciences Praxis stopped its Phase 2 epilepsy trial early because the drug was working — a rare signal. Relutrigine could hit $650M in peak US sales. And the company has an essential tremor drug heading to the FDA with $2.5B+ potential. Two pipeline wins in one day. ---